-
The American Journal of Psychiatry Jul 2024
Topics: Humans; Bipolar Disorder; Weight Gain; Antipsychotic Agents
PubMed: 38946281
DOI: 10.1176/appi.ajp.20240061 -
The American Journal of Psychiatry Jul 2024
Topics: Humans; Depressive Disorder, Treatment-Resistant; Medical Records
PubMed: 38946279
DOI: 10.1176/appi.ajp.20240377 -
The American Journal of Psychiatry Jul 2024
Topics: Humans; Pharmacogenetics; Mood Disorders; Cardiovascular Diseases; Mental Disorders
PubMed: 38946276
DOI: 10.1176/appi.ajp.20240428 -
The American Journal of Psychiatry Jul 2024
Topics: Bipolar Disorder; Humans; Antidepressive Agents
PubMed: 38946275
DOI: 10.1176/appi.ajp.20240411 -
The American Journal of Psychiatry Jul 2024
Topics: Humans; Brain; Multimodal Imaging; Neuroimaging; Magnetic Resonance Imaging; Brain Mapping; Depressive Disorder, Major; Stress, Psychological
PubMed: 38946274
DOI: 10.1176/appi.ajp.20240400 -
The American Journal of Psychiatry Jul 2024
Topics: Humans; Bipolar Disorder; Weight Gain; Antipsychotic Agents
PubMed: 38946272
DOI: 10.1176/appi.ajp.20240061r -
The American Journal of Psychiatry Jul 2024Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania. The evidence from randomized controlled trials, however, is limited by... (Observational Study)
Observational Study
OBJECTIVE
Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania. The evidence from randomized controlled trials, however, is limited by short treatment durations, providing little evidence for the long-term risk of antidepressant-induced mania. The authors performed a target trial emulation to compare the risk of mania among individuals with bipolar depression treated or not treated with antidepressants over a 1-year period.
METHODS
The authors emulated a target trial using observational data from nationwide Danish health registers. The study included 979 individuals with bipolar depression recently discharged from a psychiatric ward. Of these, 358 individuals received antidepressant treatment, and 621 did not. The occurrence of mania and bipolar depression over the following year was ascertained, and the intention-to-treat effect of antidepressants was analyzed by using Cox proportional hazards regression with adjustment for baseline covariates to emulate randomized open-label treatment allocation.
RESULTS
The fully adjusted analyses revealed no statistically significant associations between treatment with an antidepressant and the risk of mania in the full sample (hazard rate ratio=1.08, 95% CI=0.72-1.61), in the subsample concomitantly treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.63-2.13), and in the subsample not treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.65-2.07). Secondary analyses revealed no statistically significant association between treatment with an antidepressant and bipolar depression recurrence.
CONCLUSIONS
These findings suggest that the risk of antidepressant-induced mania is negligible and call for further studies to optimize treatment strategies for individuals with bipolar depression.
Topics: Humans; Bipolar Disorder; Antidepressive Agents; Male; Female; Denmark; Adult; Mania; Middle Aged; Registries; Proportional Hazards Models
PubMed: 38946271
DOI: 10.1176/appi.ajp.20230477 -
Nihon Yakurigaku Zasshi. Folia... 2024Major depressive disorder (MDD) is a psychiatric disorder that affects more than 300 million people worldwide and has a serious impact on society. Conventional... (Review)
Review
Major depressive disorder (MDD) is a psychiatric disorder that affects more than 300 million people worldwide and has a serious impact on society. Conventional antidepressants targeting monoamines in the brain based on the monoamine hypothesis are known to take a prolonged time to be effective or less effective in 30% of MDD patients. Hence, there is a need to develop antidepressants that are effective against treatment-resistant depression and have a new mechanism different from the monoamine hypothesis. An increasing number of research groups including us have been establishing that pituitary adenylate cyclase-activating polypeptide (PACAP) and one of its receptors, PAC1 receptor, are closely related to the etiology of stress-related diseases such as MDD. Therefore, it is strongly suggested that the PAC1 receptor is a promising target in the treatment of psychiatric disorders. We developed a novel, non-peptidic, small-molecule, high-affinity PAC1 receptor antagonists and conducted behavioral pharmacology experiments in mice to characterize a novel PAC1 receptor antagonist as a new option for MDD therapy. The results show that our novel PAC1 receptor antagonist has the potential to be a new antidepressant with a high safety profile. In this review, we would like to present the background of developing our novel PAC1 receptor antagonist and its effects on mouse models of acute stress.
Topics: Antidepressive Agents; Animals; Humans; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Drug Development; Depressive Disorder, Major; Molecular Targeted Therapy
PubMed: 38945904
DOI: 10.1254/fpj.24008 -
Nihon Yakurigaku Zasshi. Folia... 2024Major Depressive Disorder (MDD) poses a significant global health burden, with 30-40% patients developing resistance to standard clinical antidepressants, such as... (Review)
Review
Major Depressive Disorder (MDD) poses a significant global health burden, with 30-40% patients developing resistance to standard clinical antidepressants, such as selective serotonin reuptake inhibitors and tricyclic antidepressants. In 2016, Carhart-Harris and colleagues reported that psilocybin, the hallucinogenic compound derived from magic mushrooms, exhibits rapid and enduring antidepressant effects in patients with treatment-resistant depression. Subsequent clinical studies have found the therapeutic potential of psilocybin in MDD, depressive episode in bipolar disorder, anorexia, and drug addiction. In 2018 and 2019, the U.S. Food and Drug Administration designated psilocybin as a "breakthrough medicine" for treatment-resistant depression and MDD, respectively. Notably, the side effects of psilocybin are limited to transient and mild issues, such as headache and fatigue, suggesting its safety. In 2023, we published a review on the role of serotonin 5-HT receptors in the antidepressant effects of serotonergic psychedelics (Nihon Yakurigaku Zasshi, Volume 158, Issue 3, Page 229-232). Here, we present our study alongside the latest clinical and preclinical research on the antidepressant effects of psilocybin and provide an overview of the potential and issues related to psilocybin therapy.
Topics: Psilocybin; Humans; Animals; Antidepressive Agents; Hallucinogens; Depressive Disorder, Major; Receptor, Serotonin, 5-HT2A
PubMed: 38945903
DOI: 10.1254/fpj.24007 -
Physical Medicine and Rehabilitation... Aug 2024Traumatic brain injury (TBI) is a complex condition associated with a range of persistent symptoms including headaches, cognitive dysfunction, mental fatigue, insomnia,... (Review)
Review
Complementary and Integrative Medicine in Treating Headaches, Cognitive Dysfunction, Mental Fatigue, Insomnia, and Mood Disorders Following Traumatic Brain Injury: A Comprehensive Review.
Traumatic brain injury (TBI) is a complex condition associated with a range of persistent symptoms including headaches, cognitive dysfunction, mental fatigue, insomnia, and mood disorders. Conventional treatments for TBI-related symptoms can be insufficient, leading to interest in complementary and integrative medicine (CIM) approaches. This comprehensive article examines the existing literature on CIM modalities, including mind-body interventions, acupuncture/acupressure, herbal remedies, nutritional supplements, biofeedback, yoga, and tai chi in the context of managing secondary complications following TBI. The article highlights potential benefits and limitations of CIM modalities, while acknowledging the need for further research to better establish efficacy and safety in this specific population.
Topics: Humans; Brain Injuries, Traumatic; Mood Disorders; Complementary Therapies; Sleep Initiation and Maintenance Disorders; Integrative Medicine; Headache; Cognitive Dysfunction; Mental Fatigue
PubMed: 38945657
DOI: 10.1016/j.pmr.2024.02.013